| Abstract | OBJECTIVE: The primary objective of this study was to explore the efficacy and safety of combined chemotherapy with CPT-11 and UFT in patients with advanced/metastatic colorectal cancer. METHODS: Twenty-two patients with metastatic colorectal cancer were enrolled in the phase I trial and 35 patients (including eight patients treated at level 4 during phase I) were evaluated in the phase II trial. Treatment consisted of two 35-day cycles of combination chemotherapy with CPT-11 and UFT. During phase I, CPT-11 was administered on days 1 and 15 as an intravenous infusion over 90 min at four different dose levels, starting from a dose of 80 mg/m2 (level 1). During phase II, the dose of CPT-11 was fixed at 150 mg/m2 based on the results of the phase I study. UFT was administered orally at a fixed dose of 300 mg/m2 on days 1-28, followed by a 1-week drug holiday, during each course (35 days). RESULTS: The maximum tolerated dose (MTD) of CPT-11 was determined to be 150 mg/m2 during the phase I trial. The major toxicities detected during phase II in 35 patients receiving CPT-11 at this recommended dose were grade 3/4 neutropenia in nine patients (25.7%) and grade 3/4 anorexia in six patients (11.4%). No severe adverse events occurred. The overall response rate and the median overall survival time was 22.9% (8/35) and 23.9 months for all patients, respectively. For pre-treated patients they were 26.3% (5/19) and 25.1 months, respectively. CONCLUSION: This combination of CPT-11 and UFT is considered to be both feasible and relatively safe. The response rate of the patients receiving CPT-11 at a dose of 150 mg/m2 was comparable to that reported previously for 5-FU-based regimens coupled with CPT-11, and this regimen can probably be beneficial for patients with pre-treated advanced colorectal cancer on an outpatient basis. |
| Authors | Naohiro Tomita, Mutsumi Fukunaga, Shu Okamura, Hiroyuki Narahara, Noriya Uedo, Ryu Ishihara, Hideyuki Ishida, Hiroshi Furukawa, Masahiro Gotoh, Hiroya Takiuchi
(Affiliation: Department of Surgery, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan. ntomita at hyo_med.ac.jp)
|
| Journal | Japanese journal of clinical oncology
(Jpn J Clin Oncol)
Vol. 37
Issue 7
Pg. 521-7
(Jul 2007)
ISSN: 1465-3621 Japan |
| PMID | 17720738
(Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article)
|
| Chemical References |
- Antineoplastic Agents, Phytogenic
- irinotecan
- Tegafur
- Uracil
- 1-UFT protocol
- Camptothecin
|
| Topics |
- Adenocarcinoma
(drug therapy, mortality)
- Administration, Oral
- Adolescent
- Adult
- Aged
- Antineoplastic Agents, Phytogenic
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use, toxicity)
- Camptothecin
(administration & dosage, analogs & derivatives)
- Colorectal Neoplasms
(drug therapy, mortality)
- Humans
- Infusions, Intravenous
- Middle Aged
- Neoplasm Recurrence, Local
- Tegafur
(administration & dosage)
- Uracil
(administration & dosage)
|
